Zanubrutinib showed superior long-term safety and efficacy over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma, with improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback